These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37751084)
21. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
22. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A; JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385 [TBL] [Abstract][Full Text] [Related]
23. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. Brito-Zerón P; Gracia-Tello B; Robles A; Alguacil A; Bonet M; De-Escalante B; Noblejas-Mosso A; Gómez-de-la-Torre R; Akasbi M; Pérez-de-Lis M; Pérez-Alvarez R; Ramos-Casals M; On Behalf Of The SarcoGEAS-Semi Registry Viruses; 2021 May; 13(6):. PubMed ID: 34071924 [TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators Intensive Care Med; 2021 Jan; 47(1):60-73. PubMed ID: 33211135 [TBL] [Abstract][Full Text] [Related]
25. Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia. Sullerot C; Bouiller K; Laborde C; Gilis M; Fèvre A; Hacquin A; Manckoundia P; Hoefler F; Bermejo M; Mendes A; Serratrice C; Prendki V; Sanchez S; Putot A; Geroscience; 2022 Apr; 44(2):573-583. PubMed ID: 34993763 [TBL] [Abstract][Full Text] [Related]
26. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study. Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437 [TBL] [Abstract][Full Text] [Related]
27. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452 [TBL] [Abstract][Full Text] [Related]
28. Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019-positive patients predicted for higher mortality and prolonged intensive care unit and hospital stays in a multisite healthcare system. Erben Y; Franco-Mesa C; Gloviczki P; Stone W; Quinones-Hinojoas A; Meltzer AJ; Lin M; Greenway MRF; Hamid O; Devcic Z; Toskich B; Ritchie C; Lamb CJ; De Martino RR; Siegel J; Farres H; Hakaim AG; Sanghavi DK; Li Y; Rivera C; Moreno-Franco P; O'Keefe NL; Gopal N; Marquez CP; Huang JF; Kalra M; Shields R; Prudencio M; Gendron T; McBane R; Park M; Hoyne JB; Petrucelli L; O'Horo JC; Meschia JF J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1361-1370.e1. PubMed ID: 33836287 [TBL] [Abstract][Full Text] [Related]
29. Association of α1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark. Thomsen RW; Christiansen CF; Heide-Jørgensen U; Vogelstein JT; Vogelstein B; Bettegowda C; Tamang S; Athey S; Sørensen HT JAMA Netw Open; 2021 Feb; 4(2):e2037053. PubMed ID: 33566109 [TBL] [Abstract][Full Text] [Related]
30. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R; BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637 [TBL] [Abstract][Full Text] [Related]
32. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
33. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. Lund LC; Kristensen KB; Reilev M; Christensen S; Thomsen RW; Christiansen CF; Støvring H; Johansen NB; Brun NC; Hallas J; Pottegård A PLoS Med; 2020 Sep; 17(9):e1003308. PubMed ID: 32898149 [TBL] [Abstract][Full Text] [Related]
34. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635 [TBL] [Abstract][Full Text] [Related]
35. Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial. Muller M; Lefebvre F; Harlay ML; Glady L; Becker G; Muller C; Aberkane O; Tawk M; Julians M; Romoli A; Hecketsweiler S; Schneider F; Pottecher J; Chamaraux-Tran TN Trials; 2021 Feb; 22(1):131. PubMed ID: 33573681 [TBL] [Abstract][Full Text] [Related]
36. Early prone positioning in acute respiratory distress syndrome related to COVID-19: a propensity score analysis from the multicentric cohort COVID-ICU network-the ProneCOVID study. Le Terrier C; Sigaud F; Lebbah S; Desmedt L; Hajage D; Guérin C; Pugin J; Primmaz S; Terzi N; Crit Care; 2022 Mar; 26(1):71. PubMed ID: 35331332 [TBL] [Abstract][Full Text] [Related]
37. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL). Mariani J; Tajer C; Antonietti L; Inserra F; Ferder L; Manucha W Trials; 2021 Feb; 22(1):111. PubMed ID: 33522946 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study. Al Sulaiman K; Korayem GB; Altebainawi AF; Al Harbi S; Alissa A; Alharthi A; Kensara R; Alfahed A; Vishwakarma R; Al Haji H; Almohaimid N; Al Zumai O; Alrubayan F; Asiri A; Alkahtani N; Alolayan A; Alsohimi S; Melibari N; Almagthali A; Aljahdali S; Alenazi AA; Alsaeedi AS; Al Ghamdi G; Al Faris O; Alqahtani J; Al Qahtani J; Alshammari KA; Alshammari KI; Aljuhani O Crit Care; 2022 Oct; 26(1):304. PubMed ID: 36192801 [TBL] [Abstract][Full Text] [Related]
39. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473 [TBL] [Abstract][Full Text] [Related]
40. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study. Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]